Literature DB >> 32478631

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.

Kyle T Greenway1, Nicolas Garel1, Lisa Jerome2, Allison A Feduccia3.   

Abstract

INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind both conventional and psychedelic paradigms, including the evolution of this knowledge and the associated explanatory frameworks. We explore how psychedelics have provided insights about psychiatric illnesses and treatments over the past decades. We discuss limitations to early explanatory models while highlighting and comparing the psychological and biological mechanisms underlying many psychiatric treatments.
METHODS: A narrative review was conducted based on a search in Medline/Pubmed up to January 1st, 2020, and iterative retrieval of references from recent reviews and clinical trials. EXPERT OPINION: The contextual model of the common factors of psychotherapy provides a powerful perspective on psychotherapy, antidepressants, and psychedelics, as well as 3,4-methylenedioxymethamphetamine (MDMA) and ketamine. It aligns well with key tenets of psychedelic-assisted psychotherapy. Conventional antidepressants and especially psychedelics may improve the efficacy of psychotherapy via neurochemical changes and increased environmental sensitivity. Combined treatments hold significant promise for advancing the knowledge and treatment of many forms of psychopathology.

Entities:  

Keywords:  Psychedelics; antidepressants; ketamine; ketamine-assisted psychotherapy; lsd; mdma; mdma-assisted psychotherapy; psilocybin; psychedelic-assisted psychotherapy; psychiatry; psychotherapy

Mesh:

Substances:

Year:  2020        PMID: 32478631     DOI: 10.1080/17512433.2020.1772054

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  4 in total

Review 1.  Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Authors:  Nina Schimmel; Joost J Breeksema; Sanne Y Smith-Apeldoorn; Jolien Veraart; Wim van den Brink; Robert A Schoevers
Journal:  Psychopharmacology (Berl)       Date:  2021-11-23       Impact factor: 4.530

2.  Toward Synergies of Ketamine and Psychotherapy.

Authors:  David S Mathai; Victoria Mora; Albert Garcia-Romeu
Journal:  Front Psychol       Date:  2022-03-25

3.  Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.

Authors:  Charles L Raison; Rakesh Jain; Andrew D Penn; Steven P Cole; Saundra Jain
Journal:  Front Psychiatry       Date:  2022-03-15       Impact factor: 4.157

Review 4.  The molecular pathophysiology of depression and the new therapeutics.

Authors:  Haihua Tian; Zhenyu Hu; Jia Xu; Chuang Wang
Journal:  MedComm (2020)       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.